Table 5 Logistic regression of dose escalation status and treatment year adjusting for potential confounders of the NCDB cohort with RT dose exclusions during Period 1 (2004–2010)
NCDB 2004–2010 (N = 11,949) | ||||
|---|---|---|---|---|
Study sample characteristics | Escalated dose | Standard dose | Escalated vs standard dose | |
No. (%) | No. (%) | Adjusted OR (95% CI) | P* | |
Treatment year | 1.11 (1.08–1.25) | <0.0001 | ||
Age | ||||
≤ 67 yo | 708 (57) | 5856 (55) | ref | |
> 67 yo | 524 (43) | 4861 (45) | 0.89 (0.79–1.01) | 0.07 |
Sex | ||||
Male | 689 (56) | 6223 (58) | ref | |
Female | 543 (44) | 4494 (42) | 1.10 (0.97–1.25) | 0.12 |
Race | ||||
White | 1062 (86) | 9143 (85) | ref | |
Non-white | 162 (13) | 1497 (14) | 0.91 (0.76–1.09) | 0.31 |
Missing | 8 (1) | 77 (1) | Not included | |
Histology | ||||
Squamous | 498 (40) | 4333 (40) | ref | |
Non-Squamous | 734 (60) | 6384 (60) | 1.04 (0.89–1.15) | 0.82 |
Derived AJCC v6 T-stage | ||||
T0-2 | 826 (67) | 7286 (68) | ref | |
T3 | 406 (33) | 3431 (32) | 1.03 (0.91–1.18) | 0.60 |
Charlson/Deyo Score | ||||
0 | 786 (64) | 6916 (64) | ref | |
1 | 320 (26) | 2778 (64) | 0.98 (0.85–1.13) | 0.81 |
2+ | 126 (10) | 1023 (10) | 1.05 (0.85–1.29) | 0.64 |
Hospital typea | ||||
Community | 901 (73) | 7991 (75) | ref | |
Academic | 331 (27) | 2726 (25) | 1.09 (0.95–1.25) | 0.23 |
Hospital settinga | ||||
Metro | 904 (73.4) | 7777 (73) | ref | |
Non-metro | 274 (22.2) | 2476 (23) | 0.96 (0.83–1.11) | 0.59 |
Missing | 54 (4.4) | 464 (4) | Not included | |